Therapy of hepatitis C

Seminars in Liver Disease

Volumn 15, Issue 1, 1995, Pages 82-91

  Fried, Michael W ^b   Hoofnagle, Jay H ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON;

BACKACHE; BONE MARROW DEPRESSION; CHRONIC HEPATITIS; FATIGUE; FEVER; HEPATITIS C; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INFLUENZA; MYALGIA; PRIORITY JOURNAL; REVIEW;

EID: 0028899746     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007265     Document Type: Review

References (85)

1. Alter MJ, Mast EE: The epidemiology of viral hepatitis in the United States. Gastroenterology Clinics of North America 23:437-455, 1994.
2. Alberti A, Realdi G: Parenterally acquired non-A, non-B (type C) hepatitis. In: McIntyre N, Benhamou J-P, Bircher J, Rizzetto M, Rodes J (Eds): Oxford Textbook of Clinical Hepatology. Oxford, Oxford University Press, 1991.
3. Omata M, Yokosuka O, Takano S, et al: Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 338:914-915, 1991.
4. Alberti A, Chemello L, Benvegnu L, et al: Pilot study of interferon alpha-2a therapy in preventing chronic evolution of acute hepatitis C. In: Hollinger RB, Lemon S, Margolis H (Eds): Viral Hepatitis and Liver Disease. Baltimore, Williams and Wilkins, 1991.
5. Viladomiu L, Genesca J, Esteban J, et al: Interferon alpha in acute post-transfusion hepatitis C: A randomized, controlled trial. Hepatology 15:767-769, 1992.
6. Lampertico P, Rumi M, Romeo R, et al: A multicenter randomized controlled trial of recombinant interferon alpha 2b in patients with acute transfusion associated hepatitis C. Hepatology 19:19-22, 1994.
7. Takano S, Satomura Y, Omata M, et al: Effects of interferon beta on non-A, non-B acute hepatitis: A prospective, randomized, controlled-dose study. Gastroenterology 107:805-811, 1994.
8. Simonetti RG, Camma C, Fiorello F, et al: Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis: A case controlled study. Ann Intern Med 116:97-102, 1992.
9. Hoofnagle JH, Mullen KD, Jones DB, et al: Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: A preliminary report. N Engl J Med 315:1575-1578, 1987.
10. Davis GL, Balart LA, Schiff ER, et al: Treatment of chronic hepatitis C with recombinant interferon alfa: A multicenter randomized, controlled trial. N Engl J Med 321:1501-1505, 1989.
11. Di Bisceglie AM, Martin P, Kassianides C, et al: Recombinant interferon alfa therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial. N Engl J Med 321:1506-1510, 1989.
12. Marcellin P, Boyer N, Giostra E, et al: Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: A multicenter randomized controlled trial from France. Hepatology 13:393-397, 1991.
13. Saracco G, Rosina F, Torrani Cerenzia MR, et al: A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis. J Hepatology 11:S43-S49, 1990.
14. Ferenci P, Vogel W, Pristautz H, et al: One-year treatment of chronic non-A, non-B hepatitis with interferon alfa-2b. J Hepatology 11:S50-S56, 1990.
15. Weiland O, Schvarcz R, Wejstal R, et al: Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alfa-2b: Swedish experience. J Hepatology 11:S57-S62, 1990.
16. Gomez-Rubio M, Porres JC, Castillo I, et al: Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group. J Hepatology 11:S63-S67, 1990.
17. Realdi G, Diodata G, Bonetti P, et al: Recombinant human interferon alfa-2a in community-acquired non-A, non-B chronic active hepatitis: Preliminary results of a randomized, controlled trial. J Hepatology 11:S68-S71, 1990.
18. Causse X, Godinot H, Chevallier M, et al: Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 101:497-502, 1991.
19. Shindo M, Di Bisceglie AM, Cheung L, et al: Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 115:700-704, 1991.
20. Fong T-L, Shindo M, Feinstone SM, et al. Detection of replicative intermediates of hepatitis C viral RNA in liver and serum of patients with chronic hepatitis C. J Clin Invest 88:1058-1060, 1991.
21. Shindo M, Di Bisceglie AM, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis C treated with alpha interferon. Hepatology 15:1013-1016, 1992.
22. 2b. Hepatology 18:1300-1305, 1993.
23. Castillo I, Bartolome J, Navas S, et al: Virological and biochemical long-term follow-up of patients with chronic hepatitis C treated with interferon. Hepatology 19:1342-1346, 1994.
24. Hoofnagle JH. Therapy of acute and chronic viral hepatitis. Advances in Internal Medicine 39:241-275, 1994.
25. Smedley H, Katrak M, Sikora K, et al: Neurological effects of recombinant human interferon. Br Med J 286:262-264, 1983.
26. Renault PF, Hoofnagle JH, Park Y, et al: Psychiatric complications of long-term interferon alpha therapy. Arch Intern Med 147:1577-1580, 1987.
27. McDonald EM, Mann AH, Thomas HC: Interferons as mediators of psychiatric morbidity: An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers. Lancet 2:1175-1178, 1987.
28. Kassianides C, Di Bisceglie AM, Hoofnagle JH, et al: Alpha interferon therapy in patients with decompensated chronic type B hepatitis. In: Zuckerman AJ (Ed): Viral Hepatitis and Liver Disease. New York, Alan R Liss, 1988.
29. Janssen HLA, Berk L, Vermeulen M, Schalm SW: Seizures associated with low-dose alpha-interferon. Lancet 336:1580 (letter), 1990.
30. Averbuch SD, Austin HA, Sherwin SA, et al: Acute interestitial nephritis with the nephrotic syndrome following recombinant leukocyte interferon therapy for mycosis fungoides. N Engl J Med 310:32-35, 1984.
31. Deyton LR, Walker RE, Kovacs JA, et al: Reversible cardiac dysfunction associated with interferon alfa therapy in AIDS patients with Kaposi's sarcoma. N Engl J Med 321:1246-1249, 1989.
32. Mayet W-J, Hess G, Gerken G, et al: Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology 10:24-28, 1989.
33. Lisker-Melman M, Di Bisceglie AM, Usala SJ, et al: Development of thyroid disease during therapy of chronic viral hepatitis with alpha interferon. Gastroenterology 102:2155-2160, 1992.
34. Watanabe U, Hashimoto E, Hisamitsu T, et al: The risk factor for development of thyroid disease during interferon-α therapy for chronic hepatitis C. Am J Gastroenterol 89:399-403, 1994.
35. Baudine E, Marcellin P, Pouteau M, et al. Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C. Clin Endocrinol 39:657-661, 1993.
36. McLaughlin P, Talpaz M, Quesada JR: Immune thrombocytopenia following alpha interferon therapy in patients with cancer. JAMA 254:1353-1354, 1985.
37. Akard LP, Hoffman R, Elias L, Saiers JH: Alpha interferon and immune hemolytic anemia. Ann Intern Med 105:306 (letter), 1986.
38. Chazerain P, Meyer O, Kahn MR: Rheumatoid arthritis-like disease after alpha-interferon therapy. Ann Intern Med 116:427 (letter), 1992.
39. Diodati G, Bonetti P, Noventa F, et al: Treatment of chronic hepatitis C with recombinant human interferon-alpha 2a: Results of a randomized, controlled trial. Hepatology 19:1-5, 1994.
40. Bonetti P, Diodati G, Drago C, et al: Interferon antibodies in patients with chronic hepatitis C infection treated with recombinant interferon alpha-2a. J Hepatology 20:416-420, 1994.
41. Pol S, Jaffredo B, Nalpas B, Savada C, Berthelot P, Brechot C: Predictive value of HCV viremia after 3 months in the monitoring of antiviral therapy. Hepatology 20:159 (abstr.), 1994.
42. Shindo M, Di Bisceglie AM, Hoofnagle JH: Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology 102:1406-1408, 1992.
43. Papo T, Marcellin P, Bernuau J, et al: Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med 116:51-53, 1992.
44. Fried MW, Draguesku JO, Shindo M, et al: Clinical and serological differentiation of autoimmune and hepatitis C virus-related chronic hepatitis. Dig Dis Sci 38:631-636, 1993.
45. Hoofnagle JH, Di Bisceglie AM: Antiviral therapy of viral hepatitis. In: Galasso GJ, Whitley RJ, Merigan TC (Eds): Antiviral Agents and Viral Diseases of Man. 3rd ed. New York, Raven Press, 1990.
46. Tsubota A, Chayama K, Ikeda K, et al: Factors predictive of response to interferon-a therapy in hepatitis C virus infection. Hepatology 19:1088-1094, 1994.
47. Camps J, Crisostomo S, Garcia-Granero M, et al: Prediction of the response of chronic hepatitis C to interferon alfa: A statistical analysis of pretreatment variables. Gut 34:1714-1717, 1993.
48. Jouet P, Roudot-Thoraval F, Dhumeaux D, Metreau JM: Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterol 106:686-690, 1994.
49. Lau JYN, Davis GL, Kniffen J, et al: Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 341:1501-1504, 1993.
50. Yoshioka K, Kakumu S, Wakita T, et al: Detection of hepatitis C virus by polymerase chain reaction and response to interferon-a therapy: Relationship to genotypes of hepatitis C virus. Hepatology 16:293-299, 1992.
51. Okada S, Akahane Y, Suzuki H, et al: The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 16:619-624, 1992.
52. Kako M, Kanai K, Okamoto H: Clearance of hepatitis C virus after interferon therapy in regard with virus genotype. International Symposium on Viral Hepatitis and Liver Disease 240 (Abstr.), 1993.
53. Mahaney K, Tedeschi V, Maertens G, Di Bisceglie AM, Vergalla J, Hoofnagle JH, Sallie R: Genotypic analysis of hepatitis C virus in American patients. Hepatology 20:1405-1411, 1994.
54. Nousbaum J-B, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C: Hepatitis C virus type 1b (II) infection in France and Italy. Annals Intern Med 122:161-168, 1995.
55. Alberti A, Chemello L, Diodati G, et al: Treatment of chronic hepatitis C with different regimens of interferon alpha-2a. Hepatology 16:75A (abstr.), 1992.
56. Craxi A, Di Marco V, Lo Iacono, et al: Lymphoblastoid alpha-interferon for post-transfusion chronic hepatitis C: A randomized trial of 6 vs. 12 months treatment. J Hepatology 16:S8 (abstr.), 1992.
57. 2b for 60 weeks. Hepatology 19:280-285, 1994.
58. Marcellin P, Boyer N, Goritsas C, et al: Efficacy of a second course of alpha interferon treatment in patients with chronic hepatitis C. Hepatology 19:239 (abstr.), 1994.
59. Van Thiel DH, Friedlander L, Fagiuoli S, et al: Response to interferon a therapy is influenced by the iron content of the liver. J Hepatol 20:410-415, 1994.
60. Bacon BR, Rebholz AE, Fried MW, Di Bisceglie AM: Beneficial effect of iron reduction therapy in patients with chronic hepatitis C who failed to respond to interferon therapy. Hepatology 18:373 (abstr.), 1993.
61. 2 production by cultured liver biopsy in patients with chronic viral hepatitis: Can non-steroidal anti-inflammatory drugs improve the therapeutic response to Interferon? J Hepatol 19:228-231, 1993.
62. Andreone P, Cursaro C, Gramenzi A, et al: Alfa-interferon plus indomethacin combined therapy for non-responder patients with chronic hepatitis C. Hepatology 18:659 (abstr.), 1993.
63. Andreone P, Cursaro C, Gramenzi A, et al: Pilot study of α-interferon and ketoprofen combined therapy in non-responder patients with chronic hepatitis C: An interim report. Gastroenterology 106:859A, 1994.
64. Patterson JL, Fernandez-Larsson R: Molecular mechanisms of action of ribavirin. Rev Inf Dis 12:1139-1146, 1990.
65. Reichard O, Andersson J, Schvarcz R, Weiland O: Ribavirin treatment for chronic hepatitis C. Lancet 337:1058-1061, 1991.
66. Di Bisceglie AM, Shindo M, Fong T-L, et al: A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 16:649-654, 1992.
67. Camps J, Garcia N, Riezu-Boj JI, Civeira MP, Prieto J. Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon. J Hepatol 19:408-412, 1993.
68. Di Bisceglie AM, Fried MW, Swain MG, et al: Randomized, double-blind placebo controlled trial of ribavirin therapy for chronic hepatitis C. Hepatology 18:145 (abstr.), 1993.
69. Brillanti S, Garson J, Foli M, et al: A pilot study of combination therapy with ribavirin plus interferon-alfa for interferon-alfa resistant chronic hepatitis C. Gastroenterology 107:812-817, 1994.
70. Alberti A, Morsica G, Chemello L, et al: Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 340:697-698, 1992.
71. Naito M, Hayashi N, Hagiwara H, et al: Serum hepatitis C virus RNA quantity and histologic features of hepatitis C virus carriers with persistently normal ALT levels. Hepatology 19:871-875, 1994.
72. Di Bisceglie AM, Goodman ZD, Ishak KG, et al: Long-term histopathological follow-up of chronic post-transfusion hepatitis. Hepatology 14:969-974, 1991.
73. Ruiz-Moreno M, Rua MJ, Castillo I, et al: Treatment of children with chronic hepatitis C with recombinant interferon-alpha: A pilot study. Hepatology 16:882-885, 1992.
74. Martin P, Di Bisceglie AM, Kassianides C, et al: Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus. Gastroenterology 97:1559-1561, 1989.
75. Martin P, Munoz SJ, Di Bisceglie AM, et al: Recurrence of hepatitis C infection following orthotopic liver transplantation Hepatology 13:719-721, 1991.
76. Ferrell LD, Wright TL, Roberts J, et al: Hepatitis C viral infection in liver transplant recipients. Hepatology 16:865-876, 1992.
77. Pereira BJG, Milford EL, Kirkman RL, Levey AS: Transmission of hepatitis C virus by organ transplantation. N Engl J Med 325:454-460, 1991.
78. Chan TM, Lok ASF, Cheng IKP, Chan RT: A prospective study of hepatitis C virus infection among renal transplant recipients. Gastroenterology 104:862-868, 1993.
79. Chan TM, Lok ASF, Cheng IKP, Chan RT: Prevalence of hepatitis C virus infection in hemodialysis patients: A longitudinal study comparing the results of RNA and antibody assays. Hepatology 17:5-8, 1993.
80. Boyer N, Marcellin P, Degott C, et al: Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. J Infect Dis 165:723-724, 1992.
81. Marriott E, Navas S, Del Romero J, et al: Treatment with recombinant alpha-interferon of chronic hepatitis C in anti-HIV positive patients. J Med Virol 40:107-111, 1993.
82. Wright HI, Gavaler JS, Van Thiel DH. Preliminary experience with alpha-2b interferon therapy of viral hepatitis in liver allograft recipients. Transplantation 53:121-124, 1992.
83. Ferri C, Greco F, Longombardo G, et al: Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia. Arthritis Rheum 34:1606-1610, 1991.
84. Misiani R, Bellavita P, Fenili D, et al: Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 117:573-577, 1992.
85. Misiani R, Bellavita P, Fenili D, et al: Interferon alfa-2a in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 330:751-756, 1994.